GTS Securities’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

GTS Securities’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-13,796	Closed	-$132K	–	1669
2024 Q4	$132K	Buy	+13,796	New	+$72K	0.01%	1152

Other funds holding PSTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

GTS Securities's PSTX Position: Q1 2025 in Review

GTS Securities sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 13,796 shares — an estimated $132K sold.

GTS Securities first reported a position in PSTX in Q4 2024 and held it in 1 quarter. The position peaked at $132K in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

GTS Securities reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
GTS Securities sold 13,796 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $132K.
GTS Securities first reported a position in Poseida Therapeutics, Inc. Common Stock in Q4 2024 and held it in 1 quarter.
GTS Securities's Poseida Therapeutics, Inc. Common Stock position peaked at $132K in Q4 2024.
1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on GTS Securities's 13F filing for Q1 2025, filed 15 May 2025.